R & D is worth nearly 5 billion yuan a year! How good are the three major products of domestic pharmaceutical enterprises?

The R & D expenses of listed pharmaceutical companies with wonderful contents have always been one of the focuses of the public According to statistics, the R & D expenses of Hengrui pharmaceutical, China biopharmaceutical and Fosun Pharmaceutical exceeded 1.5 billion yuan in 2017, totaling nearly 5 billion yuan So where does their money go? What are the best sellers? ", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> R & D expenses of Hengrui Pharmaceutical (unit: 100 million yuan) Hengrui pharmaceutical adheres to the strategy of R & D and innovation and continues to increase R & D investment In 2017, it reached 1.759 billion yuan, up 48.53% year on year At present, the company focuses on anti-tumor drugs, surgical anesthetics, contrast agents, major diseases and areas where there is no effective treatment drugs, forming a huge product R & D pipeline Basic information of main R & D projects (unit: 10000 yuan) it is understood that two innovative drugs of Hengrui medicine, irexib and apatinib, have been put on the market, and products such as shr-a1403, shr-9146 and shr-1316 injection have been approved to carry out clinical trials overseas In addition, at present, the production of pyrrolidine, desflurane for inhalation, paclitaxel for injection (albumin binding type) has been declared, and PD-1 antibody drugs have entered the clinical phase III Basic information of main business of Hengrui medicine (unit: 10000 yuan) According to the annual report, Hengrui medicine achieved a total revenue of 11.2 billion yuan in 2017, including 5.722 billion yuan in anti-tumor, 5.722 billion yuan in anesthetics and contrast agents, and apatinib, an innovative drug, is in a rapid release period In addition to entering the medical insurance catalog, the future market sales scale is expected to further improve, and the company maintains a leading position in the anti-tumor drug market; anesthetics 3.6 billion yuan, with dexmedetomidine, sevoflurane and atracurium as the three leading varieties in the anesthesia market, the anesthesia sector will continue to maintain a stable growth; the contrast agent reached 1.895 billion yuan, an increase of 44.85% year-on-year, and the product sales growth is strong With the continuous expansion and enrichment of its contrast agent product line and the development of the distribution mode, it will maintain a rapid growth trend   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; Color: rgb (62, 62, 62); border style: none none solid; text align: Center; border bottom width: 1px; border bottom color: rgb (0, 0, 0); box sizing: border box! Im portant; word wrap: break word! Im portant; "> in recent years, China's biopharmaceutical R & D expenses (unit: 100 million yuan) have been reported frequently Runzhong (entecavir) dispersible tablet has obtained drug registration approval successively through consistency evaluation, enrotinib hydrochloride capsule, compound sodium acetate ringer injection and ganaric acetate injection, etc., showing its strong R & D strength Research and development of biopharmaceutical in China: biopharmaceutical in China has been focusing on the research and development of products in the fields of cardio cerebrovascular, liver disease, anti-tumor, analgesia and respiratory system The R & D expenses increased from RMB 1.105 billion in 2015 to RMB 1.595 billion in 2017 In 2017, 33 clinical applications and 38 products were submitted; 54 clinical approvals and 2 production approvals were approved At present, there are 477 products in research, including 54 drugs for cardiovascular and cerebrovascular diseases, 37 drugs for liver diseases, 202 anti-tumor drugs, 22 drugs for respiratory system, 26 drugs for diabetes and 136 other drugs Main product sources of China's biopharmaceutical industry: in the annual report of China's biopharmaceutical industry in 2017, the revenue of China's biopharmaceutical industry reached 14.819 billion yuan, up 9.4% year on year, and the compound growth rate of revenue in 2013-2017 reached 17.2% The main varieties, such as Runzhong, Tianqing Kamei, elanpine and tuotuotuo, kept a reasonable growth The pain management products, flurbiprofen axetil injection and flurbiprofen cataplasm, increased significantly The transformation marketing mode of gaisanchun calcitriol pill achieved ideal results The sales of new anal and intestinal drugs, azopine, achieved a breakthrough growth The respiratory system drugs, Tianqing Shule, Hepatology drugs, Tianding tablet and GANZE were used Capsule, antineoplastic drugs, such as genico capsule, qingweike, enishu tablets, etc rise steadily It is worth mentioning that China's biopharmaceutical has sold 32 single products worth more than RMB 100 million, an increase of 4 over the same period of 2016 Among them, Runzhong (entecavir) dispersible tablets reached RMB 3.169 billion, Tianqing Ganmei injection, KAIFEN injection and Kaishi Injection all exceeded RMB 1 billion   none="shifuMouseDownStyle('shifu_bus_002')" style="margin: 1em auto; padding: 0px; max-width: 100%; font-size: 17px; letter-spacing: 0.544px; widows: 1; font-family: -apple-system-font, Bl inkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif; line-height: 25.6px; color: rgb(62, 62, 62); border-style: none none solid; text-align: center; border-bottom-width: 1px; border-bottom-color: rgb(0, 0, 0); box-sizing: border-box !im portant; word-wrap: break-word !im portant; "> R & D expenses of Fosun Pharma (unit: 100 million yuan) in recent years, Fosun Pharma continued to increase R & D investment, from 830 million yuan in 2015 to 1529 million yuan in 2017 At present, Fosun Pharmaceutical has established an interactive and integrated R & D system in the layout of China, the United States, India, etc., and built a platform for chemical innovative drugs, biological drugs, high-value generic drugs and cell immunity Fosun said that in the future, the products under research will help to further enrich and improve the product line and enhance its competitiveness and profitability Basic information of main R & D projects (unit: 10000 yuan) Note: Amlodipine Besylate tablets have passed the consistency evaluation in February 2018 Fosun Pharmaceutical continues to strengthen the product layout of anti-tumor drugs According to the annual report, as of the end of the reporting period, 6 monoclonal antibody varieties (including an innovative monoclonal antibody) and 11 indications have been approved in clinical trials in mainland China In addition to the newly acquired gland Pharma, 171 projects are under research, including new drugs, generic drugs, biological similar drugs and consistency evaluation, 9 projects are applying for clinical trials, 29 projects are undergoing clinical trials, 27 projects are waiting for approval and listing; in early 2018, amlodipine besylate tablets (schlida) passed the consistency evaluation of generic drugs Important R & D projects planned for the new year: Fosun Pharmaceutical has established an interactive and integrated R & D system in the layout of China, the United States, India, etc., and built a platform for chemical innovative drugs, biological drugs, high-value generic drugs and cell immunity Fosun said that in the future, the products under research will help to further enrich and improve the product line and enhance its competitiveness and profitability In 2017, Fosun Pharmaceutical's revenue reached 18.534 billion yuan, a year-on-year increase of 26.69% Among them, the revenue of pharmaceutical manufacturing and R & D business reached 13.195 billion yuan, a year-on-year increase of 28.62%; the revenue of medical service business reached 2.088 billion yuan, a year-on-year increase of 24.49% Main business of Fosun Pharmaceutical (unit: 10000 yuan) In addition to Pharma, there are 21 pharmaceutical products and series with sales volume of more than 100 million yuan in the pharmaceutical sector The sales volume of 5 products or series, including calf serum deproteinized injection (odegin), reduced glutathione series (Atomolan needle, Atomolan tablets), alprostadil dry emulsion for injection (util), cephalosporin for injection series, and Yanhuning for injection (sadolika), exceeds the sales volume Over 500 million yuan The sales of febuxostat tablets (Unilever), pivastatin calcium tablets (Bangzhi) and new compound aloe capsules (Koi) have maintained a rapid growth Recently, these three pharmaceutical companies also reported frequently Hengrui pharmaceutical's heavyweight product 19K was approved for marketing, China Bio pharmaceutical's Runzhong (entecavir) dispersible tablet passed the consistency evaluation, Fosun Pharmaceutical's carbamic acid injection was approved for clinical use In the future, what surprises they will bring to the market remains to be seen Data source: annual report of listed companies, sales base of domestic listed companies of minenet